| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30,390 |
21,647 |
$1.33M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
8,963 |
6,245 |
$367K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,125 |
3,172 |
$259K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,334 |
2,413 |
$238K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,021 |
2,133 |
$196K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,917 |
3,270 |
$185K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,649 |
1,855 |
$174K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
5,693 |
4,754 |
$152K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,651 |
1,201 |
$117K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
473 |
334 |
$36K |
| 87428 |
|
799 |
393 |
$28K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,602 |
991 |
$17K |
| 92551 |
|
2,340 |
1,665 |
$17K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
918 |
675 |
$14K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
585 |
301 |
$13K |
| 96160 |
|
1,156 |
797 |
$10K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,164 |
323 |
$10K |
| 99173 |
|
2,195 |
1,624 |
$10K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,323 |
641 |
$9K |
| 96127 |
|
1,439 |
1,014 |
$5K |
| 87634 |
|
72 |
69 |
$4K |
| 36416 |
|
2,304 |
1,571 |
$3K |
| 85018 |
|
1,187 |
848 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
76 |
61 |
$2K |
| 83655 |
|
131 |
102 |
$2K |
| 87807 |
|
155 |
100 |
$1K |
| 96161 |
|
1,622 |
1,146 |
$1K |
| 0071A |
|
54 |
26 |
$981.60 |
| 99174 |
|
101 |
74 |
$820.95 |
| 0072A |
|
24 |
12 |
$684.80 |
| 96380 |
|
20 |
14 |
$398.91 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
56 |
24 |
$391.60 |
| 80061 |
Lipid panel |
20 |
15 |
$263.28 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
218 |
120 |
$187.11 |
| 90686 |
|
3,431 |
1,999 |
$134.79 |
| 90670 |
|
1,564 |
1,001 |
$80.00 |
| 90660 |
|
15 |
15 |
$30.00 |
| 90680 |
|
806 |
563 |
$13.64 |
| 90723 |
|
1,252 |
860 |
$13.64 |
| 90647 |
|
987 |
687 |
$10.77 |
| 90656 |
|
371 |
324 |
$10.21 |
| 90651 |
|
37 |
27 |
$5.00 |
| 90734 |
|
13 |
12 |
$5.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
56 |
24 |
$3.36 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
12 |
12 |
$3.35 |
| 90677 |
|
447 |
360 |
$0.95 |
| 90661 |
|
92 |
74 |
$0.04 |
| 3008F |
|
7,767 |
5,601 |
$0.01 |
| 90674 |
|
614 |
446 |
$0.00 |
| 91307 |
|
135 |
67 |
$0.00 |
| 90633 |
|
178 |
144 |
$0.00 |
| 91300 |
|
31 |
15 |
$0.00 |
| 90672 |
|
30 |
18 |
$0.00 |